Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

By /

Rallybio Corporation presented clinical data in a poster from the Phase 1 first-in-human single ascending dose clinical study in healthy participants of RLYB116.

Scroll to Top